Navigation Links
Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
Date:6/1/2010

act in a complementary manner in the central nervous system. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior.  In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.  Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements  

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, approval for Contrave and the Company's belief that this product candidate may be an important therapeutic option in the treatment of obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, wi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
2. Logical Therapeutics Secures $16.9M Series C Financing Round
3. Sorrento Therapeutics Awarded NIH Grant for MRSA Program
4. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
5. New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season
6. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
7. Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
8. Osseon Therapeutics Demonstrates to the European Medical Community How to Think Outside The Balloon When Treating Vertebral Compression Fractures
9. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
10. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
11. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 26, 2007 /PRNewswire-FirstCall/ --,Replidyne, Inc. today announced ... a novel topical antibiotic that has shown ... including,methicillin-resistant S. aureus (MRSA). The results of ... REP8839 appears safe,well-tolerated and associated with low ...
... in a randomized phase II/III clinical trial,anticipated ... /PRNewswire-FirstCall/ -- Cell,Therapeutics, Inc. (CTI) announced the ... with pixantrone (BBR,2778) resulted in minimal or ... significant cardiac damage.,The studies compared the cardiac ...
Cached Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... MOC-etomidate detected no sudden drops in blood pressure , ... of a common general anesthesia has been developed that may ... rats put under with MOC-etomidate, a chemically altered version of ... blood pressure to drop suddenly or slow adrenal gland activity, ...
... efforts, but a nasal spray version might help , THURSDAY, ... of doses of injectable swine flu vaccine U.S. officials now ... coming in the form of a nasal spray. , Since ... doses spread a month apart, the amount of vaccine will ...
... , , Potential Size of ... Texas Medicaid Program; Seniors, Care at Risk, Local ... Texas, July 23 /PRNewswire-USNewswire/ -- Expressing growing concern ... as part of ongoing health reform negotiations could have a disastrous impact ...
... , TUCSON, Ariz., July 23 ... today announced that it is scheduled to report financial results for its ... the market closes. , , Providence will ... 8:00 a.m. Arizona and PDT) Tuesday, August 11, 2009, to discuss its ...
... remaining life in wheelchair, nursing facilities after nurse failed to alert physician ... KENT, Wash., July 23 A King County Superior Court ... million yesterday for a medical center,s failure to alert her physician of ... , The jury concluded the actions of Renton, ...
... jolly, good year for Dr. Bhimu Patil. The director ... been named a fellow by three professional entities for his ... title of "fellow" is bestowed by scientific societies to designate ... Patil was first honored in January 2009 as fellow ...
Cached Medicine News:Health News:New Anesthesia May Be Safer for Critically Ill 2Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 2Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 3Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 4Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 5Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 6Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 7Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 8Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 9Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 10Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 11Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 12Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 13Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 14Health News:Expressing Growing Concern, THCA Urges Texas Congressional Delegation to Protect Seniors' Medicare-Funded Nursing Home Care as Health Reform Debate Proceeds 2Health News:Providence Service Corporation to Report Second Quarter 2009 Results on Monday, August 10th After the Market Closes 2Health News:Providence Service Corporation to Report Second Quarter 2009 Results on Monday, August 10th After the Market Closes 3Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 3Health News:Patil: For he's a jolly good science fellow 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: